Compare Stocks → Did you make $29,000 two days with AI options trades? (From Prosper Trading Academy) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:BIVINASDAQ:JAGXNYSE:LCINASDAQ:NXTCNASDAQ:XERS Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBIVIBioVie$0.53-0.7%$0.98$0.48▼$8.94$21.16M0.92.51 million shs364,727 shsJAGXJaguar Health$0.08+3.0%$0.08$0.05▼$1.22$3.81M1.3138.22 million shs20.92 million shsLCILannett$1.54$0.64▼$3.72$7.38M0.9592,067 shs280,600 shsNXTCNextCure$2.06+6.5%$1.48$0.98▼$2.09$57.47M0.37239,447 shs111,358 shsXERSXeris Biopharma$2.22+8.8%$2.62$1.31▼$3.26$311.80M2.372.36 million shs1.98 million shsBeginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBIVIBioVie+0.47%-13.42%-56.62%-56.08%-93.82%JAGXJaguar Health+5.65%-8.76%+21.50%-54.97%-90.65%LCILannett0.00%0.00%0.00%0.00%-56.06%NXTCNextCure-1.78%+37.23%+29.00%+68.26%+26.47%XERSXeris Biopharma-0.49%-6.85%-34.41%-13.56%+53.38%Did you make $29,000 two days with AI options trades? (Ad)What if it was possible to find options trades on autopilot… Using A.I. to find the ones with the highest profit potential… And nearly perfect win rates… You can grab your free copy of my "Ultimate Guide to A.I. Options Trading" by clicking the link below:Click Here To Get Your Free CopyMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBIVIBioVie1.3174 of 5 stars3.33.00.00.03.20.00.0JAGXJaguar HealthN/AN/AN/AN/AN/AN/AN/AN/ALCILannettN/AN/AN/AN/AN/AN/AN/AN/ANXTCNextCure4.5415 of 5 stars3.53.00.04.42.91.71.3XERSXeris Biopharma4.5225 of 5 stars3.52.00.04.24.42.50.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBIVIBioVie2.50Moderate Buy$8.001,409.43% UpsideJAGXJaguar HealthN/AN/AN/AN/ALCILannettN/AN/AN/AN/ANXTCNextCure3.00Buy$6.00191.28% UpsideXERSXeris Biopharma3.00Buy$4.88119.59% UpsideCurrent Analyst RatingsLatest XERS, BIVI, NXTC, JAGX, and LCI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/28/2024XERSXeris BiopharmaOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$5.003/22/2024NXTCNextCureHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$5.00 ➝ $8.003/20/2024NXTCNextCureNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.003/7/2024XERSXeris BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$5.50 ➝ $6.00(Data available from 3/28/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBIVIBioVieN/AN/AN/AN/A$0.42 per shareN/AJAGXJaguar Health$11.96M0.32N/AN/A($0.32) per share-0.23LCILannett$340.58M0.00N/AN/A($23.34) per share0.00NXTCNextCureN/AN/AN/AN/A$4.10 per shareN/AXERSXeris Biopharma$163.91M1.90N/AN/A($0.05) per share-44.40Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBIVIBioVie-$50.26M-$1.17N/A∞N/AN/A-332.18%-137.85%5/10/2024 (Estimated)JAGXJaguar Health-$47.45MN/A0.00N/AN/A-370.40%-1,191.67%-79.95%4/1/2024 (Confirmed)LCILannett-$231.62M-$18.88N/AN/AN/A-62.40%N/A-13.39%N/ANXTCNextCure-$62.72M-$2.25N/AN/AN/AN/A-47.03%-42.59%5/2/2024 (Estimated)XERSXeris Biopharma-$62.26M-$0.45N/AN/AN/A-37.98%-610.76%-19.15%5/14/2024 (Estimated)Latest XERS, BIVI, NXTC, JAGX, and LCI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/1/2024N/AJAGXJaguar HealthN/AN/AN/AN/AN/AN/A 3/6/2024Q4 2023XERSXeris Biopharma-$0.09-$0.10-$0.01-$0.10$45.50 million$44.39 million 2/12/2024Q2 2024BIVIBioVie-$0.32-$0.22+$0.10-$0.22N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBIVIBioVieN/AN/AN/AN/AN/AJAGXJaguar HealthN/AN/AN/AN/AN/ALCILannettN/AN/AN/AN/AN/ANXTCNextCureN/AN/AN/AN/AN/AXERSXeris BiopharmaN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBIVIBioVieN/A1.471.47JAGXJaguar Health22.001.771.10LCILannettN/A2.231.39NXTCNextCureN/A16.3816.38XERSXeris Biopharma49.271.641.23OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBIVIBioVie4.59%JAGXJaguar Health12.04%LCILannett40.28%NXTCNextCure42.65%XERSXeris Biopharma42.75%Insider OwnershipCompanyInsider OwnershipBIVIBioVie4.80%JAGXJaguar Health0.16%LCILannett13.12%NXTCNextCure11.90%XERSXeris Biopharma4.36%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableBIVIBioVie1839.92 million38.01 millionOptionableJAGXJaguar Health6050.76 million50.68 millionNo DataLCILannett81010.77 million9.35 millionOptionableNXTCNextCure8227.90 million24.58 millionOptionableXERSXeris Biopharma377140.45 million134.33 millionOptionableXERS, BIVI, NXTC, JAGX, and LCI HeadlinesSourceHeadlineXeris Biopharma (NASDAQ:XERS) Now Covered by Oppenheimermarketbeat.com - March 28 at 8:29 AMXeris Biopharma Surpasses 2023 Expectations with Strategic Moves Poised for 2024 Growthproactiveinvestors.com - March 18 at 9:49 PMHere's What Analysts Are Forecasting For Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) After Its Annual Resultsfinance.yahoo.com - March 9 at 1:59 PMXeris Biopharma (XERS) Q4 2023 Earnings Call Transcriptseekingalpha.com - March 8 at 7:43 PMBrokers Offer Predictions for Xeris Biopharma Holdings, Inc.'s Q2 2024 Earnings (NASDAQ:XERS)marketbeat.com - March 8 at 6:35 AMXeris Biopharma Holdings Inc (XERS) Reports Robust Revenue Growth in Q4 and Full Year 2023finance.yahoo.com - March 7 at 2:41 PMXeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q4 2023 Earnings Call Transcriptinsidermonkey.com - March 7 at 1:01 PMHC Wainwright Boosts Xeris Biopharma (NASDAQ:XERS) Price Target to $6.00marketbeat.com - March 7 at 8:20 AMQ4 2023 Xeris Biopharma Holdings Inc Earnings Callfinance.yahoo.com - March 7 at 12:19 AMXeris Biopharma Shares Drop After Weak 4Q Resultsmarketwatch.com - March 6 at 7:18 PMXeris Pharmaceuticals GAAP EPS of -$0.10 in-line, revenue of $44.39M beats by $0.84Mmsn.com - March 6 at 7:18 PMXERS Stock Earnings: Xeris Biopharma Holdings Meets EPS, Beats Revenue for Q4 2023investorplace.com - March 6 at 2:00 PMXeris Biopharma secures $200M in capital in debt refinancing deal; sees big 4Q revenue jumpproactiveinvestors.com - March 6 at 9:57 AMXeris Biopharma (XERS) Reports Q4 Loss, Lags Revenue Estimateszacks.com - March 6 at 9:16 AMXeris Biopharma (NASDAQ:XERS) Issues Earnings Results, Misses Estimates By $0.01 EPSmarketbeat.com - March 6 at 7:49 AMXeris Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Eventsbusinesswire.com - March 6 at 7:02 AMXeris Refinances Its $150M Senior Secured Term Loan Facility With Hayfin Capitalbusinesswire.com - March 6 at 7:00 AMWhy Xeris (XERS) Might Surprise This Earnings Seasonzacks.com - March 5 at 10:46 AMXeris Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on March 6, 2024businesswire.com - February 28 at 7:00 AM3 Breakout Stocks Under $5 to Buy for More Upsidetheglobeandmail.com - February 23 at 7:13 PMXeris to Present at the Oppenheimer 34th Annual Healthcare Life Science Conferencefinance.yahoo.com - February 5 at 9:27 AMBig Game or Small, Here's How to Go About Stalking a Traderealmoney.thestreet.com - February 3 at 6:45 PMXeris inks licensing deal with Amgen on former Horizon drugchicagobusiness.com - January 12 at 9:32 AMXeris Biopharma jumps on news of Amgen dealthepharmaletter.com - January 12 at 9:32 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsBioVieNASDAQ:BIVIBioVie Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.Jaguar HealthNASDAQ:JAGXJaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including Short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; supportive care for diarrhea relief in inflammatory bowel diseases; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, it develops NP-300, a second-generation proprietary anti-secretory antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea; and Canalevia, an oral plant-based drug candidate to treat chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs. The company was founded in 2013 and is headquartered in San Francisco, California.LannettNYSE:LCILannett Co., Inc. engages in the development, manufacture, marketing, and distribution of generic pharmaceutical products. It offers products in different forms including capsules, tablets, liquids, powders, and sprays. The company was founded in 1942 and is headquartered in Trevose, PA.NextCureNASDAQ:NXTCNextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. The company has a license agreement with Yale University. NextCure, Inc. was incorporated in 2015 and is headquartered in Beltsville, Maryland.Xeris BiopharmaNASDAQ:XERSXeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.